Pharma & Healthcare
Global Immuno-oncology Drugs Market Research Report 2025
- Sep 09, 25
- ID: 496993
- Pages: 117
- Figures: 114
- Views: 3
This report aims to provide a comprehensive presentation of the global market for Immuno-oncology Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Immuno-oncology Drugs.
The Immuno-oncology Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Immuno-oncology Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Immuno-oncology Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen, Inc
AstraZeneca, Plc
Bristol-Myers Squibb
Celgene Corporation
Eli Lilly and Company
Merck & Co.
Hoffmann-La Roche AG
Johnson & Johnson
Novartis International AG
AbbVie, Inc.
Pfizer Inc.
Sanofi S.A.
EMD Serono, Inc.
Gilead Sciences Inc.
Prometheus Therapeutics & Diagnostics
Aduro BioTech
Galena Biopharma
Bavarian Nordic
Celldex Therapeutics
ImmunoCellular Therapeutics
Incyte
Dendreon Corporation
Agilent Technologies Inc.
Agenus Inc.
Enzo Biochem, Inc.
Lonza Group
Bio-Rad Laboratories, Inc.
Avantor, Inc.
Spring Bank Pharmaceuticals, Inc.
Ferring Pharmaceuticals
Segment by Type
Immune Checkpoint Inhibitors
Immune System Modulators
Cancer Vaccines
Oncolytic Virus
Others
Segment by Application
Hospitals
Clinics
Ambulatory Surgical Centers
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Immuno-oncology Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The Immuno-oncology Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Immuno-oncology Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Immuno-oncology Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen, Inc
AstraZeneca, Plc
Bristol-Myers Squibb
Celgene Corporation
Eli Lilly and Company
Merck & Co.
Hoffmann-La Roche AG
Johnson & Johnson
Novartis International AG
AbbVie, Inc.
Pfizer Inc.
Sanofi S.A.
EMD Serono, Inc.
Gilead Sciences Inc.
Prometheus Therapeutics & Diagnostics
Aduro BioTech
Galena Biopharma
Bavarian Nordic
Celldex Therapeutics
ImmunoCellular Therapeutics
Incyte
Dendreon Corporation
Agilent Technologies Inc.
Agenus Inc.
Enzo Biochem, Inc.
Lonza Group
Bio-Rad Laboratories, Inc.
Avantor, Inc.
Spring Bank Pharmaceuticals, Inc.
Ferring Pharmaceuticals
Segment by Type
Immune Checkpoint Inhibitors
Immune System Modulators
Cancer Vaccines
Oncolytic Virus
Others
Segment by Application
Hospitals
Clinics
Ambulatory Surgical Centers
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Immuno-oncology Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Immuno-oncology Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Immune Checkpoint Inhibitors
1.2.3 Immune System Modulators
1.2.4 Cancer Vaccines
1.2.5 Oncolytic Virus
1.2.6 Others
1.3 Market by Application
1.3.1 Global Immuno-oncology Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Immuno-oncology Drugs Market Perspective (2020-2031)
2.2 Global Immuno-oncology Drugs Growth Trends by Region
2.2.1 Global Immuno-oncology Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Immuno-oncology Drugs Historic Market Size by Region (2020-2025)
2.2.3 Immuno-oncology Drugs Forecasted Market Size by Region (2026-2031)
2.3 Immuno-oncology Drugs Market Dynamics
2.3.1 Immuno-oncology Drugs Industry Trends
2.3.2 Immuno-oncology Drugs Market Drivers
2.3.3 Immuno-oncology Drugs Market Challenges
2.3.4 Immuno-oncology Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Immuno-oncology Drugs Players by Revenue
3.1.1 Global Top Immuno-oncology Drugs Players by Revenue (2020-2025)
3.1.2 Global Immuno-oncology Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Immuno-oncology Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Immuno-oncology Drugs Revenue
3.4 Global Immuno-oncology Drugs Market Concentration Ratio
3.4.1 Global Immuno-oncology Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Immuno-oncology Drugs Revenue in 2024
3.5 Global Key Players of Immuno-oncology Drugs Head office and Area Served
3.6 Global Key Players of Immuno-oncology Drugs, Product and Application
3.7 Global Key Players of Immuno-oncology Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Immuno-oncology Drugs Breakdown Data by Type
4.1 Global Immuno-oncology Drugs Historic Market Size by Type (2020-2025)
4.2 Global Immuno-oncology Drugs Forecasted Market Size by Type (2026-2031)
5 Immuno-oncology Drugs Breakdown Data by Application
5.1 Global Immuno-oncology Drugs Historic Market Size by Application (2020-2025)
5.2 Global Immuno-oncology Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Immuno-oncology Drugs Market Size (2020-2031)
6.2 North America Immuno-oncology Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Immuno-oncology Drugs Market Size by Country (2020-2025)
6.4 North America Immuno-oncology Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Immuno-oncology Drugs Market Size (2020-2031)
7.2 Europe Immuno-oncology Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Immuno-oncology Drugs Market Size by Country (2020-2025)
7.4 Europe Immuno-oncology Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Immuno-oncology Drugs Market Size (2020-2031)
8.2 Asia-Pacific Immuno-oncology Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Immuno-oncology Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific Immuno-oncology Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Immuno-oncology Drugs Market Size (2020-2031)
9.2 Latin America Immuno-oncology Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Immuno-oncology Drugs Market Size by Country (2020-2025)
9.4 Latin America Immuno-oncology Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Immuno-oncology Drugs Market Size (2020-2031)
10.2 Middle East & Africa Immuno-oncology Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Immuno-oncology Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa Immuno-oncology Drugs Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Amgen, Inc
11.1.1 Amgen, Inc Company Details
11.1.2 Amgen, Inc Business Overview
11.1.3 Amgen, Inc Immuno-oncology Drugs Introduction
11.1.4 Amgen, Inc Revenue in Immuno-oncology Drugs Business (2020-2025)
11.1.5 Amgen, Inc Recent Development
11.2 AstraZeneca, Plc
11.2.1 AstraZeneca, Plc Company Details
11.2.2 AstraZeneca, Plc Business Overview
11.2.3 AstraZeneca, Plc Immuno-oncology Drugs Introduction
11.2.4 AstraZeneca, Plc Revenue in Immuno-oncology Drugs Business (2020-2025)
11.2.5 AstraZeneca, Plc Recent Development
11.3 Bristol-Myers Squibb
11.3.1 Bristol-Myers Squibb Company Details
11.3.2 Bristol-Myers Squibb Business Overview
11.3.3 Bristol-Myers Squibb Immuno-oncology Drugs Introduction
11.3.4 Bristol-Myers Squibb Revenue in Immuno-oncology Drugs Business (2020-2025)
11.3.5 Bristol-Myers Squibb Recent Development
11.4 Celgene Corporation
11.4.1 Celgene Corporation Company Details
11.4.2 Celgene Corporation Business Overview
11.4.3 Celgene Corporation Immuno-oncology Drugs Introduction
11.4.4 Celgene Corporation Revenue in Immuno-oncology Drugs Business (2020-2025)
11.4.5 Celgene Corporation Recent Development
11.5 Eli Lilly and Company
11.5.1 Eli Lilly and Company Company Details
11.5.2 Eli Lilly and Company Business Overview
11.5.3 Eli Lilly and Company Immuno-oncology Drugs Introduction
11.5.4 Eli Lilly and Company Revenue in Immuno-oncology Drugs Business (2020-2025)
11.5.5 Eli Lilly and Company Recent Development
11.6 Merck & Co.
11.6.1 Merck & Co. Company Details
11.6.2 Merck & Co. Business Overview
11.6.3 Merck & Co. Immuno-oncology Drugs Introduction
11.6.4 Merck & Co. Revenue in Immuno-oncology Drugs Business (2020-2025)
11.6.5 Merck & Co. Recent Development
11.7 Hoffmann-La Roche AG
11.7.1 Hoffmann-La Roche AG Company Details
11.7.2 Hoffmann-La Roche AG Business Overview
11.7.3 Hoffmann-La Roche AG Immuno-oncology Drugs Introduction
11.7.4 Hoffmann-La Roche AG Revenue in Immuno-oncology Drugs Business (2020-2025)
11.7.5 Hoffmann-La Roche AG Recent Development
11.8 Johnson & Johnson
11.8.1 Johnson & Johnson Company Details
11.8.2 Johnson & Johnson Business Overview
11.8.3 Johnson & Johnson Immuno-oncology Drugs Introduction
11.8.4 Johnson & Johnson Revenue in Immuno-oncology Drugs Business (2020-2025)
11.8.5 Johnson & Johnson Recent Development
11.9 Novartis International AG
11.9.1 Novartis International AG Company Details
11.9.2 Novartis International AG Business Overview
11.9.3 Novartis International AG Immuno-oncology Drugs Introduction
11.9.4 Novartis International AG Revenue in Immuno-oncology Drugs Business (2020-2025)
11.9.5 Novartis International AG Recent Development
11.10 AbbVie, Inc.
11.10.1 AbbVie, Inc. Company Details
11.10.2 AbbVie, Inc. Business Overview
11.10.3 AbbVie, Inc. Immuno-oncology Drugs Introduction
11.10.4 AbbVie, Inc. Revenue in Immuno-oncology Drugs Business (2020-2025)
11.10.5 AbbVie, Inc. Recent Development
11.11 Pfizer Inc.
11.11.1 Pfizer Inc. Company Details
11.11.2 Pfizer Inc. Business Overview
11.11.3 Pfizer Inc. Immuno-oncology Drugs Introduction
11.11.4 Pfizer Inc. Revenue in Immuno-oncology Drugs Business (2020-2025)
11.11.5 Pfizer Inc. Recent Development
11.12 Sanofi S.A.
11.12.1 Sanofi S.A. Company Details
11.12.2 Sanofi S.A. Business Overview
11.12.3 Sanofi S.A. Immuno-oncology Drugs Introduction
11.12.4 Sanofi S.A. Revenue in Immuno-oncology Drugs Business (2020-2025)
11.12.5 Sanofi S.A. Recent Development
11.13 EMD Serono, Inc.
11.13.1 EMD Serono, Inc. Company Details
11.13.2 EMD Serono, Inc. Business Overview
11.13.3 EMD Serono, Inc. Immuno-oncology Drugs Introduction
11.13.4 EMD Serono, Inc. Revenue in Immuno-oncology Drugs Business (2020-2025)
11.13.5 EMD Serono, Inc. Recent Development
11.14 Gilead Sciences Inc.
11.14.1 Gilead Sciences Inc. Company Details
11.14.2 Gilead Sciences Inc. Business Overview
11.14.3 Gilead Sciences Inc. Immuno-oncology Drugs Introduction
11.14.4 Gilead Sciences Inc. Revenue in Immuno-oncology Drugs Business (2020-2025)
11.14.5 Gilead Sciences Inc. Recent Development
11.15 Prometheus Therapeutics & Diagnostics
11.15.1 Prometheus Therapeutics & Diagnostics Company Details
11.15.2 Prometheus Therapeutics & Diagnostics Business Overview
11.15.3 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Introduction
11.15.4 Prometheus Therapeutics & Diagnostics Revenue in Immuno-oncology Drugs Business (2020-2025)
11.15.5 Prometheus Therapeutics & Diagnostics Recent Development
11.16 Aduro BioTech
11.16.1 Aduro BioTech Company Details
11.16.2 Aduro BioTech Business Overview
11.16.3 Aduro BioTech Immuno-oncology Drugs Introduction
11.16.4 Aduro BioTech Revenue in Immuno-oncology Drugs Business (2020-2025)
11.16.5 Aduro BioTech Recent Development
11.17 Galena Biopharma
11.17.1 Galena Biopharma Company Details
11.17.2 Galena Biopharma Business Overview
11.17.3 Galena Biopharma Immuno-oncology Drugs Introduction
11.17.4 Galena Biopharma Revenue in Immuno-oncology Drugs Business (2020-2025)
11.17.5 Galena Biopharma Recent Development
11.18 Bavarian Nordic
11.18.1 Bavarian Nordic Company Details
11.18.2 Bavarian Nordic Business Overview
11.18.3 Bavarian Nordic Immuno-oncology Drugs Introduction
11.18.4 Bavarian Nordic Revenue in Immuno-oncology Drugs Business (2020-2025)
11.18.5 Bavarian Nordic Recent Development
11.19 Celldex Therapeutics
11.19.1 Celldex Therapeutics Company Details
11.19.2 Celldex Therapeutics Business Overview
11.19.3 Celldex Therapeutics Immuno-oncology Drugs Introduction
11.19.4 Celldex Therapeutics Revenue in Immuno-oncology Drugs Business (2020-2025)
11.19.5 Celldex Therapeutics Recent Development
11.20 ImmunoCellular Therapeutics
11.20.1 ImmunoCellular Therapeutics Company Details
11.20.2 ImmunoCellular Therapeutics Business Overview
11.20.3 ImmunoCellular Therapeutics Immuno-oncology Drugs Introduction
11.20.4 ImmunoCellular Therapeutics Revenue in Immuno-oncology Drugs Business (2020-2025)
11.20.5 ImmunoCellular Therapeutics Recent Development
11.21 Incyte
11.21.1 Incyte Company Details
11.21.2 Incyte Business Overview
11.21.3 Incyte Immuno-oncology Drugs Introduction
11.21.4 Incyte Revenue in Immuno-oncology Drugs Business (2020-2025)
11.21.5 Incyte Recent Development
11.22 Dendreon Corporation
11.22.1 Dendreon Corporation Company Details
11.22.2 Dendreon Corporation Business Overview
11.22.3 Dendreon Corporation Immuno-oncology Drugs Introduction
11.22.4 Dendreon Corporation Revenue in Immuno-oncology Drugs Business (2020-2025)
11.22.5 Dendreon Corporation Recent Development
11.23 Agilent Technologies Inc.
11.23.1 Agilent Technologies Inc. Company Details
11.23.2 Agilent Technologies Inc. Business Overview
11.23.3 Agilent Technologies Inc. Immuno-oncology Drugs Introduction
11.23.4 Agilent Technologies Inc. Revenue in Immuno-oncology Drugs Business (2020-2025)
11.23.5 Agilent Technologies Inc. Recent Development
11.24 Agenus Inc.
11.24.1 Agenus Inc. Company Details
11.24.2 Agenus Inc. Business Overview
11.24.3 Agenus Inc. Immuno-oncology Drugs Introduction
11.24.4 Agenus Inc. Revenue in Immuno-oncology Drugs Business (2020-2025)
11.24.5 Agenus Inc. Recent Development
11.25 Enzo Biochem, Inc.
11.25.1 Enzo Biochem, Inc. Company Details
11.25.2 Enzo Biochem, Inc. Business Overview
11.25.3 Enzo Biochem, Inc. Immuno-oncology Drugs Introduction
11.25.4 Enzo Biochem, Inc. Revenue in Immuno-oncology Drugs Business (2020-2025)
11.25.5 Enzo Biochem, Inc. Recent Development
11.26 Lonza Group
11.26.1 Lonza Group Company Details
11.26.2 Lonza Group Business Overview
11.26.3 Lonza Group Immuno-oncology Drugs Introduction
11.26.4 Lonza Group Revenue in Immuno-oncology Drugs Business (2020-2025)
11.26.5 Lonza Group Recent Development
11.27 Bio-Rad Laboratories, Inc.
11.27.1 Bio-Rad Laboratories, Inc. Company Details
11.27.2 Bio-Rad Laboratories, Inc. Business Overview
11.27.3 Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Introduction
11.27.4 Bio-Rad Laboratories, Inc. Revenue in Immuno-oncology Drugs Business (2020-2025)
11.27.5 Bio-Rad Laboratories, Inc. Recent Development
11.28 Avantor, Inc.
11.28.1 Avantor, Inc. Company Details
11.28.2 Avantor, Inc. Business Overview
11.28.3 Avantor, Inc. Immuno-oncology Drugs Introduction
11.28.4 Avantor, Inc. Revenue in Immuno-oncology Drugs Business (2020-2025)
11.28.5 Avantor, Inc. Recent Development
11.29 Spring Bank Pharmaceuticals, Inc.
11.29.1 Spring Bank Pharmaceuticals, Inc. Company Details
11.29.2 Spring Bank Pharmaceuticals, Inc. Business Overview
11.29.3 Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Introduction
11.29.4 Spring Bank Pharmaceuticals, Inc. Revenue in Immuno-oncology Drugs Business (2020-2025)
11.29.5 Spring Bank Pharmaceuticals, Inc. Recent Development
11.30 Ferring Pharmaceuticals
11.30.1 Ferring Pharmaceuticals Company Details
11.30.2 Ferring Pharmaceuticals Business Overview
11.30.3 Ferring Pharmaceuticals Immuno-oncology Drugs Introduction
11.30.4 Ferring Pharmaceuticals Revenue in Immuno-oncology Drugs Business (2020-2025)
11.30.5 Ferring Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Immuno-oncology Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Immune Checkpoint Inhibitors
1.2.3 Immune System Modulators
1.2.4 Cancer Vaccines
1.2.5 Oncolytic Virus
1.2.6 Others
1.3 Market by Application
1.3.1 Global Immuno-oncology Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Immuno-oncology Drugs Market Perspective (2020-2031)
2.2 Global Immuno-oncology Drugs Growth Trends by Region
2.2.1 Global Immuno-oncology Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Immuno-oncology Drugs Historic Market Size by Region (2020-2025)
2.2.3 Immuno-oncology Drugs Forecasted Market Size by Region (2026-2031)
2.3 Immuno-oncology Drugs Market Dynamics
2.3.1 Immuno-oncology Drugs Industry Trends
2.3.2 Immuno-oncology Drugs Market Drivers
2.3.3 Immuno-oncology Drugs Market Challenges
2.3.4 Immuno-oncology Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Immuno-oncology Drugs Players by Revenue
3.1.1 Global Top Immuno-oncology Drugs Players by Revenue (2020-2025)
3.1.2 Global Immuno-oncology Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Immuno-oncology Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Immuno-oncology Drugs Revenue
3.4 Global Immuno-oncology Drugs Market Concentration Ratio
3.4.1 Global Immuno-oncology Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Immuno-oncology Drugs Revenue in 2024
3.5 Global Key Players of Immuno-oncology Drugs Head office and Area Served
3.6 Global Key Players of Immuno-oncology Drugs, Product and Application
3.7 Global Key Players of Immuno-oncology Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Immuno-oncology Drugs Breakdown Data by Type
4.1 Global Immuno-oncology Drugs Historic Market Size by Type (2020-2025)
4.2 Global Immuno-oncology Drugs Forecasted Market Size by Type (2026-2031)
5 Immuno-oncology Drugs Breakdown Data by Application
5.1 Global Immuno-oncology Drugs Historic Market Size by Application (2020-2025)
5.2 Global Immuno-oncology Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Immuno-oncology Drugs Market Size (2020-2031)
6.2 North America Immuno-oncology Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Immuno-oncology Drugs Market Size by Country (2020-2025)
6.4 North America Immuno-oncology Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Immuno-oncology Drugs Market Size (2020-2031)
7.2 Europe Immuno-oncology Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Immuno-oncology Drugs Market Size by Country (2020-2025)
7.4 Europe Immuno-oncology Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Immuno-oncology Drugs Market Size (2020-2031)
8.2 Asia-Pacific Immuno-oncology Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Immuno-oncology Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific Immuno-oncology Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Immuno-oncology Drugs Market Size (2020-2031)
9.2 Latin America Immuno-oncology Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Immuno-oncology Drugs Market Size by Country (2020-2025)
9.4 Latin America Immuno-oncology Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Immuno-oncology Drugs Market Size (2020-2031)
10.2 Middle East & Africa Immuno-oncology Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Immuno-oncology Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa Immuno-oncology Drugs Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Amgen, Inc
11.1.1 Amgen, Inc Company Details
11.1.2 Amgen, Inc Business Overview
11.1.3 Amgen, Inc Immuno-oncology Drugs Introduction
11.1.4 Amgen, Inc Revenue in Immuno-oncology Drugs Business (2020-2025)
11.1.5 Amgen, Inc Recent Development
11.2 AstraZeneca, Plc
11.2.1 AstraZeneca, Plc Company Details
11.2.2 AstraZeneca, Plc Business Overview
11.2.3 AstraZeneca, Plc Immuno-oncology Drugs Introduction
11.2.4 AstraZeneca, Plc Revenue in Immuno-oncology Drugs Business (2020-2025)
11.2.5 AstraZeneca, Plc Recent Development
11.3 Bristol-Myers Squibb
11.3.1 Bristol-Myers Squibb Company Details
11.3.2 Bristol-Myers Squibb Business Overview
11.3.3 Bristol-Myers Squibb Immuno-oncology Drugs Introduction
11.3.4 Bristol-Myers Squibb Revenue in Immuno-oncology Drugs Business (2020-2025)
11.3.5 Bristol-Myers Squibb Recent Development
11.4 Celgene Corporation
11.4.1 Celgene Corporation Company Details
11.4.2 Celgene Corporation Business Overview
11.4.3 Celgene Corporation Immuno-oncology Drugs Introduction
11.4.4 Celgene Corporation Revenue in Immuno-oncology Drugs Business (2020-2025)
11.4.5 Celgene Corporation Recent Development
11.5 Eli Lilly and Company
11.5.1 Eli Lilly and Company Company Details
11.5.2 Eli Lilly and Company Business Overview
11.5.3 Eli Lilly and Company Immuno-oncology Drugs Introduction
11.5.4 Eli Lilly and Company Revenue in Immuno-oncology Drugs Business (2020-2025)
11.5.5 Eli Lilly and Company Recent Development
11.6 Merck & Co.
11.6.1 Merck & Co. Company Details
11.6.2 Merck & Co. Business Overview
11.6.3 Merck & Co. Immuno-oncology Drugs Introduction
11.6.4 Merck & Co. Revenue in Immuno-oncology Drugs Business (2020-2025)
11.6.5 Merck & Co. Recent Development
11.7 Hoffmann-La Roche AG
11.7.1 Hoffmann-La Roche AG Company Details
11.7.2 Hoffmann-La Roche AG Business Overview
11.7.3 Hoffmann-La Roche AG Immuno-oncology Drugs Introduction
11.7.4 Hoffmann-La Roche AG Revenue in Immuno-oncology Drugs Business (2020-2025)
11.7.5 Hoffmann-La Roche AG Recent Development
11.8 Johnson & Johnson
11.8.1 Johnson & Johnson Company Details
11.8.2 Johnson & Johnson Business Overview
11.8.3 Johnson & Johnson Immuno-oncology Drugs Introduction
11.8.4 Johnson & Johnson Revenue in Immuno-oncology Drugs Business (2020-2025)
11.8.5 Johnson & Johnson Recent Development
11.9 Novartis International AG
11.9.1 Novartis International AG Company Details
11.9.2 Novartis International AG Business Overview
11.9.3 Novartis International AG Immuno-oncology Drugs Introduction
11.9.4 Novartis International AG Revenue in Immuno-oncology Drugs Business (2020-2025)
11.9.5 Novartis International AG Recent Development
11.10 AbbVie, Inc.
11.10.1 AbbVie, Inc. Company Details
11.10.2 AbbVie, Inc. Business Overview
11.10.3 AbbVie, Inc. Immuno-oncology Drugs Introduction
11.10.4 AbbVie, Inc. Revenue in Immuno-oncology Drugs Business (2020-2025)
11.10.5 AbbVie, Inc. Recent Development
11.11 Pfizer Inc.
11.11.1 Pfizer Inc. Company Details
11.11.2 Pfizer Inc. Business Overview
11.11.3 Pfizer Inc. Immuno-oncology Drugs Introduction
11.11.4 Pfizer Inc. Revenue in Immuno-oncology Drugs Business (2020-2025)
11.11.5 Pfizer Inc. Recent Development
11.12 Sanofi S.A.
11.12.1 Sanofi S.A. Company Details
11.12.2 Sanofi S.A. Business Overview
11.12.3 Sanofi S.A. Immuno-oncology Drugs Introduction
11.12.4 Sanofi S.A. Revenue in Immuno-oncology Drugs Business (2020-2025)
11.12.5 Sanofi S.A. Recent Development
11.13 EMD Serono, Inc.
11.13.1 EMD Serono, Inc. Company Details
11.13.2 EMD Serono, Inc. Business Overview
11.13.3 EMD Serono, Inc. Immuno-oncology Drugs Introduction
11.13.4 EMD Serono, Inc. Revenue in Immuno-oncology Drugs Business (2020-2025)
11.13.5 EMD Serono, Inc. Recent Development
11.14 Gilead Sciences Inc.
11.14.1 Gilead Sciences Inc. Company Details
11.14.2 Gilead Sciences Inc. Business Overview
11.14.3 Gilead Sciences Inc. Immuno-oncology Drugs Introduction
11.14.4 Gilead Sciences Inc. Revenue in Immuno-oncology Drugs Business (2020-2025)
11.14.5 Gilead Sciences Inc. Recent Development
11.15 Prometheus Therapeutics & Diagnostics
11.15.1 Prometheus Therapeutics & Diagnostics Company Details
11.15.2 Prometheus Therapeutics & Diagnostics Business Overview
11.15.3 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Introduction
11.15.4 Prometheus Therapeutics & Diagnostics Revenue in Immuno-oncology Drugs Business (2020-2025)
11.15.5 Prometheus Therapeutics & Diagnostics Recent Development
11.16 Aduro BioTech
11.16.1 Aduro BioTech Company Details
11.16.2 Aduro BioTech Business Overview
11.16.3 Aduro BioTech Immuno-oncology Drugs Introduction
11.16.4 Aduro BioTech Revenue in Immuno-oncology Drugs Business (2020-2025)
11.16.5 Aduro BioTech Recent Development
11.17 Galena Biopharma
11.17.1 Galena Biopharma Company Details
11.17.2 Galena Biopharma Business Overview
11.17.3 Galena Biopharma Immuno-oncology Drugs Introduction
11.17.4 Galena Biopharma Revenue in Immuno-oncology Drugs Business (2020-2025)
11.17.5 Galena Biopharma Recent Development
11.18 Bavarian Nordic
11.18.1 Bavarian Nordic Company Details
11.18.2 Bavarian Nordic Business Overview
11.18.3 Bavarian Nordic Immuno-oncology Drugs Introduction
11.18.4 Bavarian Nordic Revenue in Immuno-oncology Drugs Business (2020-2025)
11.18.5 Bavarian Nordic Recent Development
11.19 Celldex Therapeutics
11.19.1 Celldex Therapeutics Company Details
11.19.2 Celldex Therapeutics Business Overview
11.19.3 Celldex Therapeutics Immuno-oncology Drugs Introduction
11.19.4 Celldex Therapeutics Revenue in Immuno-oncology Drugs Business (2020-2025)
11.19.5 Celldex Therapeutics Recent Development
11.20 ImmunoCellular Therapeutics
11.20.1 ImmunoCellular Therapeutics Company Details
11.20.2 ImmunoCellular Therapeutics Business Overview
11.20.3 ImmunoCellular Therapeutics Immuno-oncology Drugs Introduction
11.20.4 ImmunoCellular Therapeutics Revenue in Immuno-oncology Drugs Business (2020-2025)
11.20.5 ImmunoCellular Therapeutics Recent Development
11.21 Incyte
11.21.1 Incyte Company Details
11.21.2 Incyte Business Overview
11.21.3 Incyte Immuno-oncology Drugs Introduction
11.21.4 Incyte Revenue in Immuno-oncology Drugs Business (2020-2025)
11.21.5 Incyte Recent Development
11.22 Dendreon Corporation
11.22.1 Dendreon Corporation Company Details
11.22.2 Dendreon Corporation Business Overview
11.22.3 Dendreon Corporation Immuno-oncology Drugs Introduction
11.22.4 Dendreon Corporation Revenue in Immuno-oncology Drugs Business (2020-2025)
11.22.5 Dendreon Corporation Recent Development
11.23 Agilent Technologies Inc.
11.23.1 Agilent Technologies Inc. Company Details
11.23.2 Agilent Technologies Inc. Business Overview
11.23.3 Agilent Technologies Inc. Immuno-oncology Drugs Introduction
11.23.4 Agilent Technologies Inc. Revenue in Immuno-oncology Drugs Business (2020-2025)
11.23.5 Agilent Technologies Inc. Recent Development
11.24 Agenus Inc.
11.24.1 Agenus Inc. Company Details
11.24.2 Agenus Inc. Business Overview
11.24.3 Agenus Inc. Immuno-oncology Drugs Introduction
11.24.4 Agenus Inc. Revenue in Immuno-oncology Drugs Business (2020-2025)
11.24.5 Agenus Inc. Recent Development
11.25 Enzo Biochem, Inc.
11.25.1 Enzo Biochem, Inc. Company Details
11.25.2 Enzo Biochem, Inc. Business Overview
11.25.3 Enzo Biochem, Inc. Immuno-oncology Drugs Introduction
11.25.4 Enzo Biochem, Inc. Revenue in Immuno-oncology Drugs Business (2020-2025)
11.25.5 Enzo Biochem, Inc. Recent Development
11.26 Lonza Group
11.26.1 Lonza Group Company Details
11.26.2 Lonza Group Business Overview
11.26.3 Lonza Group Immuno-oncology Drugs Introduction
11.26.4 Lonza Group Revenue in Immuno-oncology Drugs Business (2020-2025)
11.26.5 Lonza Group Recent Development
11.27 Bio-Rad Laboratories, Inc.
11.27.1 Bio-Rad Laboratories, Inc. Company Details
11.27.2 Bio-Rad Laboratories, Inc. Business Overview
11.27.3 Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Introduction
11.27.4 Bio-Rad Laboratories, Inc. Revenue in Immuno-oncology Drugs Business (2020-2025)
11.27.5 Bio-Rad Laboratories, Inc. Recent Development
11.28 Avantor, Inc.
11.28.1 Avantor, Inc. Company Details
11.28.2 Avantor, Inc. Business Overview
11.28.3 Avantor, Inc. Immuno-oncology Drugs Introduction
11.28.4 Avantor, Inc. Revenue in Immuno-oncology Drugs Business (2020-2025)
11.28.5 Avantor, Inc. Recent Development
11.29 Spring Bank Pharmaceuticals, Inc.
11.29.1 Spring Bank Pharmaceuticals, Inc. Company Details
11.29.2 Spring Bank Pharmaceuticals, Inc. Business Overview
11.29.3 Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Introduction
11.29.4 Spring Bank Pharmaceuticals, Inc. Revenue in Immuno-oncology Drugs Business (2020-2025)
11.29.5 Spring Bank Pharmaceuticals, Inc. Recent Development
11.30 Ferring Pharmaceuticals
11.30.1 Ferring Pharmaceuticals Company Details
11.30.2 Ferring Pharmaceuticals Business Overview
11.30.3 Ferring Pharmaceuticals Immuno-oncology Drugs Introduction
11.30.4 Ferring Pharmaceuticals Revenue in Immuno-oncology Drugs Business (2020-2025)
11.30.5 Ferring Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Immuno-oncology Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Immune Checkpoint Inhibitors
Table 3. Key Players of Immune System Modulators
Table 4. Key Players of Cancer Vaccines
Table 5. Key Players of Oncolytic Virus
Table 6. Key Players of Others
Table 7. Global Immuno-oncology Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Immuno-oncology Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Immuno-oncology Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 10. Global Immuno-oncology Drugs Market Share by Region (2020-2025)
Table 11. Global Immuno-oncology Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 12. Global Immuno-oncology Drugs Market Share by Region (2026-2031)
Table 13. Immuno-oncology Drugs Market Trends
Table 14. Immuno-oncology Drugs Market Drivers
Table 15. Immuno-oncology Drugs Market Challenges
Table 16. Immuno-oncology Drugs Market Restraints
Table 17. Global Immuno-oncology Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 18. Global Immuno-oncology Drugs Market Share by Players (2020-2025)
Table 19. Global Top Immuno-oncology Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immuno-oncology Drugs as of 2024)
Table 20. Ranking of Global Top Immuno-oncology Drugs Companies by Revenue (US$ Million) in 2024
Table 21. Global 5 Largest Players Market Share by Immuno-oncology Drugs Revenue (CR5 and HHI) & (2020-2025)
Table 22. Global Key Players of Immuno-oncology Drugs, Headquarters and Area Served
Table 23. Global Key Players of Immuno-oncology Drugs, Product and Application
Table 24. Global Key Players of Immuno-oncology Drugs, Date of Enter into This Industry
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Immuno-oncology Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 27. Global Immuno-oncology Drugs Revenue Market Share by Type (2020-2025)
Table 28. Global Immuno-oncology Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 29. Global Immuno-oncology Drugs Revenue Market Share by Type (2026-2031)
Table 30. Global Immuno-oncology Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 31. Global Immuno-oncology Drugs Revenue Market Share by Application (2020-2025)
Table 32. Global Immuno-oncology Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 33. Global Immuno-oncology Drugs Revenue Market Share by Application (2026-2031)
Table 34. North America Immuno-oncology Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. North America Immuno-oncology Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 36. North America Immuno-oncology Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 37. Europe Immuno-oncology Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 38. Europe Immuno-oncology Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 39. Europe Immuno-oncology Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 40. Asia-Pacific Immuno-oncology Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 41. Asia-Pacific Immuno-oncology Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 42. Asia-Pacific Immuno-oncology Drugs Market Size by Region (2026-2031) & (US$ Million)
Table 43. Latin America Immuno-oncology Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Latin America Immuno-oncology Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 45. Latin America Immuno-oncology Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 46. Middle East & Africa Immuno-oncology Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 47. Middle East & Africa Immuno-oncology Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 48. Middle East & Africa Immuno-oncology Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 49. Amgen, Inc Company Details
Table 50. Amgen, Inc Business Overview
Table 51. Amgen, Inc Immuno-oncology Drugs Product
Table 52. Amgen, Inc Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 53. Amgen, Inc Recent Development
Table 54. AstraZeneca, Plc Company Details
Table 55. AstraZeneca, Plc Business Overview
Table 56. AstraZeneca, Plc Immuno-oncology Drugs Product
Table 57. AstraZeneca, Plc Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 58. AstraZeneca, Plc Recent Development
Table 59. Bristol-Myers Squibb Company Details
Table 60. Bristol-Myers Squibb Business Overview
Table 61. Bristol-Myers Squibb Immuno-oncology Drugs Product
Table 62. Bristol-Myers Squibb Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 63. Bristol-Myers Squibb Recent Development
Table 64. Celgene Corporation Company Details
Table 65. Celgene Corporation Business Overview
Table 66. Celgene Corporation Immuno-oncology Drugs Product
Table 67. Celgene Corporation Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 68. Celgene Corporation Recent Development
Table 69. Eli Lilly and Company Company Details
Table 70. Eli Lilly and Company Business Overview
Table 71. Eli Lilly and Company Immuno-oncology Drugs Product
Table 72. Eli Lilly and Company Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 73. Eli Lilly and Company Recent Development
Table 74. Merck & Co. Company Details
Table 75. Merck & Co. Business Overview
Table 76. Merck & Co. Immuno-oncology Drugs Product
Table 77. Merck & Co. Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 78. Merck & Co. Recent Development
Table 79. Hoffmann-La Roche AG Company Details
Table 80. Hoffmann-La Roche AG Business Overview
Table 81. Hoffmann-La Roche AG Immuno-oncology Drugs Product
Table 82. Hoffmann-La Roche AG Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 83. Hoffmann-La Roche AG Recent Development
Table 84. Johnson & Johnson Company Details
Table 85. Johnson & Johnson Business Overview
Table 86. Johnson & Johnson Immuno-oncology Drugs Product
Table 87. Johnson & Johnson Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 88. Johnson & Johnson Recent Development
Table 89. Novartis International AG Company Details
Table 90. Novartis International AG Business Overview
Table 91. Novartis International AG Immuno-oncology Drugs Product
Table 92. Novartis International AG Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 93. Novartis International AG Recent Development
Table 94. AbbVie, Inc. Company Details
Table 95. AbbVie, Inc. Business Overview
Table 96. AbbVie, Inc. Immuno-oncology Drugs Product
Table 97. AbbVie, Inc. Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 98. AbbVie, Inc. Recent Development
Table 99. Pfizer Inc. Company Details
Table 100. Pfizer Inc. Business Overview
Table 101. Pfizer Inc. Immuno-oncology Drugs Product
Table 102. Pfizer Inc. Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 103. Pfizer Inc. Recent Development
Table 104. Sanofi S.A. Company Details
Table 105. Sanofi S.A. Business Overview
Table 106. Sanofi S.A. Immuno-oncology Drugs Product
Table 107. Sanofi S.A. Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 108. Sanofi S.A. Recent Development
Table 109. EMD Serono, Inc. Company Details
Table 110. EMD Serono, Inc. Business Overview
Table 111. EMD Serono, Inc. Immuno-oncology Drugs Product
Table 112. EMD Serono, Inc. Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 113. EMD Serono, Inc. Recent Development
Table 114. Gilead Sciences Inc. Company Details
Table 115. Gilead Sciences Inc. Business Overview
Table 116. Gilead Sciences Inc. Immuno-oncology Drugs Product
Table 117. Gilead Sciences Inc. Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 118. Gilead Sciences Inc. Recent Development
Table 119. Prometheus Therapeutics & Diagnostics Company Details
Table 120. Prometheus Therapeutics & Diagnostics Business Overview
Table 121. Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Product
Table 122. Prometheus Therapeutics & Diagnostics Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 123. Prometheus Therapeutics & Diagnostics Recent Development
Table 124. Aduro BioTech Company Details
Table 125. Aduro BioTech Business Overview
Table 126. Aduro BioTech Immuno-oncology Drugs Product
Table 127. Aduro BioTech Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 128. Aduro BioTech Recent Development
Table 129. Galena Biopharma Company Details
Table 130. Galena Biopharma Business Overview
Table 131. Galena Biopharma Immuno-oncology Drugs Product
Table 132. Galena Biopharma Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 133. Galena Biopharma Recent Development
Table 134. Bavarian Nordic Company Details
Table 135. Bavarian Nordic Business Overview
Table 136. Bavarian Nordic Immuno-oncology Drugs Product
Table 137. Bavarian Nordic Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 138. Bavarian Nordic Recent Development
Table 139. Celldex Therapeutics Company Details
Table 140. Celldex Therapeutics Business Overview
Table 141. Celldex Therapeutics Immuno-oncology Drugs Product
Table 142. Celldex Therapeutics Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 143. Celldex Therapeutics Recent Development
Table 144. ImmunoCellular Therapeutics Company Details
Table 145. ImmunoCellular Therapeutics Business Overview
Table 146. ImmunoCellular Therapeutics Immuno-oncology Drugs Product
Table 147. ImmunoCellular Therapeutics Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 148. ImmunoCellular Therapeutics Recent Development
Table 149. Incyte Company Details
Table 150. Incyte Business Overview
Table 151. Incyte Immuno-oncology Drugs Product
Table 152. Incyte Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 153. Incyte Recent Development
Table 154. Dendreon Corporation Company Details
Table 155. Dendreon Corporation Business Overview
Table 156. Dendreon Corporation Immuno-oncology Drugs Product
Table 157. Dendreon Corporation Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 158. Dendreon Corporation Recent Development
Table 159. Agilent Technologies Inc. Company Details
Table 160. Agilent Technologies Inc. Business Overview
Table 161. Agilent Technologies Inc. Immuno-oncology Drugs Product
Table 162. Agilent Technologies Inc. Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 163. Agilent Technologies Inc. Recent Development
Table 164. Agenus Inc. Company Details
Table 165. Agenus Inc. Business Overview
Table 166. Agenus Inc. Immuno-oncology Drugs Product
Table 167. Agenus Inc. Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 168. Agenus Inc. Recent Development
Table 169. Enzo Biochem, Inc. Company Details
Table 170. Enzo Biochem, Inc. Business Overview
Table 171. Enzo Biochem, Inc. Immuno-oncology Drugs Product
Table 172. Enzo Biochem, Inc. Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 173. Enzo Biochem, Inc. Recent Development
Table 174. Lonza Group Company Details
Table 175. Lonza Group Business Overview
Table 176. Lonza Group Immuno-oncology Drugs Product
Table 177. Lonza Group Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 178. Lonza Group Recent Development
Table 179. Bio-Rad Laboratories, Inc. Company Details
Table 180. Bio-Rad Laboratories, Inc. Business Overview
Table 181. Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Product
Table 182. Bio-Rad Laboratories, Inc. Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 183. Bio-Rad Laboratories, Inc. Recent Development
Table 184. Avantor, Inc. Company Details
Table 185. Avantor, Inc. Business Overview
Table 186. Avantor, Inc. Immuno-oncology Drugs Product
Table 187. Avantor, Inc. Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 188. Avantor, Inc. Recent Development
Table 189. Spring Bank Pharmaceuticals, Inc. Company Details
Table 190. Spring Bank Pharmaceuticals, Inc. Business Overview
Table 191. Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Product
Table 192. Spring Bank Pharmaceuticals, Inc. Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 193. Spring Bank Pharmaceuticals, Inc. Recent Development
Table 194. Ferring Pharmaceuticals Company Details
Table 195. Ferring Pharmaceuticals Business Overview
Table 196. Ferring Pharmaceuticals Immuno-oncology Drugs Product
Table 197. Ferring Pharmaceuticals Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 198. Ferring Pharmaceuticals Recent Development
Table 199. Research Programs/Design for This Report
Table 200. Key Data Information from Secondary Sources
Table 201. Key Data Information from Primary Sources
Table 202. Authors List of This Report
List of Figures
Figure 1. Immuno-oncology Drugs Picture
Figure 2. Global Immuno-oncology Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Immuno-oncology Drugs Market Share by Type: 2024 VS 2031
Figure 4. Immune Checkpoint Inhibitors Features
Figure 5. Immune System Modulators Features
Figure 6. Cancer Vaccines Features
Figure 7. Oncolytic Virus Features
Figure 8. Others Features
Figure 9. Global Immuno-oncology Drugs Market Size by Application (2020-2031) & (US$ Million)
Figure 10. Global Immuno-oncology Drugs Market Share by Application: 2024 VS 2031
Figure 11. Hospitals Case Studies
Figure 12. Clinics Case Studies
Figure 13. Ambulatory Surgical Centers Case Studies
Figure 14. Immuno-oncology Drugs Report Years Considered
Figure 15. Global Immuno-oncology Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 16. Global Immuno-oncology Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Immuno-oncology Drugs Market Share by Region: 2024 VS 2031
Figure 18. Global Immuno-oncology Drugs Market Share by Players in 2024
Figure 19. Global Top Immuno-oncology Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immuno-oncology Drugs as of 2024)
Figure 20. The Top 10 and 5 Players Market Share by Immuno-oncology Drugs Revenue in 2024
Figure 21. North America Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. North America Immuno-oncology Drugs Market Share by Country (2020-2031)
Figure 23. United States Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Canada Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Immuno-oncology Drugs Market Share by Country (2020-2031)
Figure 27. Germany Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. France Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. U.K. Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Italy Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Russia Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Nordic Countries Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Immuno-oncology Drugs Market Share by Region (2020-2031)
Figure 35. China Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Japan Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. South Korea Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Southeast Asia Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. India Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Australia Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Immuno-oncology Drugs Market Share by Country (2020-2031)
Figure 43. Mexico Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Brazil Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Immuno-oncology Drugs Market Share by Country (2020-2031)
Figure 47. Turkey Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Saudi Arabia Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. UAE Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Amgen, Inc Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 51. AstraZeneca, Plc Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 52. Bristol-Myers Squibb Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 53. Celgene Corporation Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 54. Eli Lilly and Company Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 55. Merck & Co. Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 56. Hoffmann-La Roche AG Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 57. Johnson & Johnson Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 58. Novartis International AG Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 59. AbbVie, Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 60. Pfizer Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 61. Sanofi S.A. Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 62. EMD Serono, Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 63. Gilead Sciences Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 64. Prometheus Therapeutics & Diagnostics Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 65. Aduro BioTech Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 66. Galena Biopharma Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 67. Bavarian Nordic Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 68. Celldex Therapeutics Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 69. ImmunoCellular Therapeutics Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 70. Incyte Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 71. Dendreon Corporation Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 72. Agilent Technologies Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 73. Agenus Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 74. Enzo Biochem, Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 75. Lonza Group Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 76. Bio-Rad Laboratories, Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 77. Avantor, Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 78. Spring Bank Pharmaceuticals, Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 79. Ferring Pharmaceuticals Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 80. Bottom-up and Top-down Approaches for This Report
Figure 81. Data Triangulation
Figure 82. Key Executives Interviewed
Table 1. Global Immuno-oncology Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Immune Checkpoint Inhibitors
Table 3. Key Players of Immune System Modulators
Table 4. Key Players of Cancer Vaccines
Table 5. Key Players of Oncolytic Virus
Table 6. Key Players of Others
Table 7. Global Immuno-oncology Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Immuno-oncology Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Immuno-oncology Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 10. Global Immuno-oncology Drugs Market Share by Region (2020-2025)
Table 11. Global Immuno-oncology Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 12. Global Immuno-oncology Drugs Market Share by Region (2026-2031)
Table 13. Immuno-oncology Drugs Market Trends
Table 14. Immuno-oncology Drugs Market Drivers
Table 15. Immuno-oncology Drugs Market Challenges
Table 16. Immuno-oncology Drugs Market Restraints
Table 17. Global Immuno-oncology Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 18. Global Immuno-oncology Drugs Market Share by Players (2020-2025)
Table 19. Global Top Immuno-oncology Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immuno-oncology Drugs as of 2024)
Table 20. Ranking of Global Top Immuno-oncology Drugs Companies by Revenue (US$ Million) in 2024
Table 21. Global 5 Largest Players Market Share by Immuno-oncology Drugs Revenue (CR5 and HHI) & (2020-2025)
Table 22. Global Key Players of Immuno-oncology Drugs, Headquarters and Area Served
Table 23. Global Key Players of Immuno-oncology Drugs, Product and Application
Table 24. Global Key Players of Immuno-oncology Drugs, Date of Enter into This Industry
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Immuno-oncology Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 27. Global Immuno-oncology Drugs Revenue Market Share by Type (2020-2025)
Table 28. Global Immuno-oncology Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 29. Global Immuno-oncology Drugs Revenue Market Share by Type (2026-2031)
Table 30. Global Immuno-oncology Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 31. Global Immuno-oncology Drugs Revenue Market Share by Application (2020-2025)
Table 32. Global Immuno-oncology Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 33. Global Immuno-oncology Drugs Revenue Market Share by Application (2026-2031)
Table 34. North America Immuno-oncology Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. North America Immuno-oncology Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 36. North America Immuno-oncology Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 37. Europe Immuno-oncology Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 38. Europe Immuno-oncology Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 39. Europe Immuno-oncology Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 40. Asia-Pacific Immuno-oncology Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 41. Asia-Pacific Immuno-oncology Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 42. Asia-Pacific Immuno-oncology Drugs Market Size by Region (2026-2031) & (US$ Million)
Table 43. Latin America Immuno-oncology Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Latin America Immuno-oncology Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 45. Latin America Immuno-oncology Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 46. Middle East & Africa Immuno-oncology Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 47. Middle East & Africa Immuno-oncology Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 48. Middle East & Africa Immuno-oncology Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 49. Amgen, Inc Company Details
Table 50. Amgen, Inc Business Overview
Table 51. Amgen, Inc Immuno-oncology Drugs Product
Table 52. Amgen, Inc Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 53. Amgen, Inc Recent Development
Table 54. AstraZeneca, Plc Company Details
Table 55. AstraZeneca, Plc Business Overview
Table 56. AstraZeneca, Plc Immuno-oncology Drugs Product
Table 57. AstraZeneca, Plc Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 58. AstraZeneca, Plc Recent Development
Table 59. Bristol-Myers Squibb Company Details
Table 60. Bristol-Myers Squibb Business Overview
Table 61. Bristol-Myers Squibb Immuno-oncology Drugs Product
Table 62. Bristol-Myers Squibb Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 63. Bristol-Myers Squibb Recent Development
Table 64. Celgene Corporation Company Details
Table 65. Celgene Corporation Business Overview
Table 66. Celgene Corporation Immuno-oncology Drugs Product
Table 67. Celgene Corporation Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 68. Celgene Corporation Recent Development
Table 69. Eli Lilly and Company Company Details
Table 70. Eli Lilly and Company Business Overview
Table 71. Eli Lilly and Company Immuno-oncology Drugs Product
Table 72. Eli Lilly and Company Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 73. Eli Lilly and Company Recent Development
Table 74. Merck & Co. Company Details
Table 75. Merck & Co. Business Overview
Table 76. Merck & Co. Immuno-oncology Drugs Product
Table 77. Merck & Co. Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 78. Merck & Co. Recent Development
Table 79. Hoffmann-La Roche AG Company Details
Table 80. Hoffmann-La Roche AG Business Overview
Table 81. Hoffmann-La Roche AG Immuno-oncology Drugs Product
Table 82. Hoffmann-La Roche AG Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 83. Hoffmann-La Roche AG Recent Development
Table 84. Johnson & Johnson Company Details
Table 85. Johnson & Johnson Business Overview
Table 86. Johnson & Johnson Immuno-oncology Drugs Product
Table 87. Johnson & Johnson Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 88. Johnson & Johnson Recent Development
Table 89. Novartis International AG Company Details
Table 90. Novartis International AG Business Overview
Table 91. Novartis International AG Immuno-oncology Drugs Product
Table 92. Novartis International AG Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 93. Novartis International AG Recent Development
Table 94. AbbVie, Inc. Company Details
Table 95. AbbVie, Inc. Business Overview
Table 96. AbbVie, Inc. Immuno-oncology Drugs Product
Table 97. AbbVie, Inc. Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 98. AbbVie, Inc. Recent Development
Table 99. Pfizer Inc. Company Details
Table 100. Pfizer Inc. Business Overview
Table 101. Pfizer Inc. Immuno-oncology Drugs Product
Table 102. Pfizer Inc. Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 103. Pfizer Inc. Recent Development
Table 104. Sanofi S.A. Company Details
Table 105. Sanofi S.A. Business Overview
Table 106. Sanofi S.A. Immuno-oncology Drugs Product
Table 107. Sanofi S.A. Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 108. Sanofi S.A. Recent Development
Table 109. EMD Serono, Inc. Company Details
Table 110. EMD Serono, Inc. Business Overview
Table 111. EMD Serono, Inc. Immuno-oncology Drugs Product
Table 112. EMD Serono, Inc. Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 113. EMD Serono, Inc. Recent Development
Table 114. Gilead Sciences Inc. Company Details
Table 115. Gilead Sciences Inc. Business Overview
Table 116. Gilead Sciences Inc. Immuno-oncology Drugs Product
Table 117. Gilead Sciences Inc. Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 118. Gilead Sciences Inc. Recent Development
Table 119. Prometheus Therapeutics & Diagnostics Company Details
Table 120. Prometheus Therapeutics & Diagnostics Business Overview
Table 121. Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Product
Table 122. Prometheus Therapeutics & Diagnostics Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 123. Prometheus Therapeutics & Diagnostics Recent Development
Table 124. Aduro BioTech Company Details
Table 125. Aduro BioTech Business Overview
Table 126. Aduro BioTech Immuno-oncology Drugs Product
Table 127. Aduro BioTech Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 128. Aduro BioTech Recent Development
Table 129. Galena Biopharma Company Details
Table 130. Galena Biopharma Business Overview
Table 131. Galena Biopharma Immuno-oncology Drugs Product
Table 132. Galena Biopharma Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 133. Galena Biopharma Recent Development
Table 134. Bavarian Nordic Company Details
Table 135. Bavarian Nordic Business Overview
Table 136. Bavarian Nordic Immuno-oncology Drugs Product
Table 137. Bavarian Nordic Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 138. Bavarian Nordic Recent Development
Table 139. Celldex Therapeutics Company Details
Table 140. Celldex Therapeutics Business Overview
Table 141. Celldex Therapeutics Immuno-oncology Drugs Product
Table 142. Celldex Therapeutics Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 143. Celldex Therapeutics Recent Development
Table 144. ImmunoCellular Therapeutics Company Details
Table 145. ImmunoCellular Therapeutics Business Overview
Table 146. ImmunoCellular Therapeutics Immuno-oncology Drugs Product
Table 147. ImmunoCellular Therapeutics Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 148. ImmunoCellular Therapeutics Recent Development
Table 149. Incyte Company Details
Table 150. Incyte Business Overview
Table 151. Incyte Immuno-oncology Drugs Product
Table 152. Incyte Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 153. Incyte Recent Development
Table 154. Dendreon Corporation Company Details
Table 155. Dendreon Corporation Business Overview
Table 156. Dendreon Corporation Immuno-oncology Drugs Product
Table 157. Dendreon Corporation Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 158. Dendreon Corporation Recent Development
Table 159. Agilent Technologies Inc. Company Details
Table 160. Agilent Technologies Inc. Business Overview
Table 161. Agilent Technologies Inc. Immuno-oncology Drugs Product
Table 162. Agilent Technologies Inc. Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 163. Agilent Technologies Inc. Recent Development
Table 164. Agenus Inc. Company Details
Table 165. Agenus Inc. Business Overview
Table 166. Agenus Inc. Immuno-oncology Drugs Product
Table 167. Agenus Inc. Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 168. Agenus Inc. Recent Development
Table 169. Enzo Biochem, Inc. Company Details
Table 170. Enzo Biochem, Inc. Business Overview
Table 171. Enzo Biochem, Inc. Immuno-oncology Drugs Product
Table 172. Enzo Biochem, Inc. Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 173. Enzo Biochem, Inc. Recent Development
Table 174. Lonza Group Company Details
Table 175. Lonza Group Business Overview
Table 176. Lonza Group Immuno-oncology Drugs Product
Table 177. Lonza Group Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 178. Lonza Group Recent Development
Table 179. Bio-Rad Laboratories, Inc. Company Details
Table 180. Bio-Rad Laboratories, Inc. Business Overview
Table 181. Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Product
Table 182. Bio-Rad Laboratories, Inc. Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 183. Bio-Rad Laboratories, Inc. Recent Development
Table 184. Avantor, Inc. Company Details
Table 185. Avantor, Inc. Business Overview
Table 186. Avantor, Inc. Immuno-oncology Drugs Product
Table 187. Avantor, Inc. Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 188. Avantor, Inc. Recent Development
Table 189. Spring Bank Pharmaceuticals, Inc. Company Details
Table 190. Spring Bank Pharmaceuticals, Inc. Business Overview
Table 191. Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Product
Table 192. Spring Bank Pharmaceuticals, Inc. Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 193. Spring Bank Pharmaceuticals, Inc. Recent Development
Table 194. Ferring Pharmaceuticals Company Details
Table 195. Ferring Pharmaceuticals Business Overview
Table 196. Ferring Pharmaceuticals Immuno-oncology Drugs Product
Table 197. Ferring Pharmaceuticals Revenue in Immuno-oncology Drugs Business (2020-2025) & (US$ Million)
Table 198. Ferring Pharmaceuticals Recent Development
Table 199. Research Programs/Design for This Report
Table 200. Key Data Information from Secondary Sources
Table 201. Key Data Information from Primary Sources
Table 202. Authors List of This Report
List of Figures
Figure 1. Immuno-oncology Drugs Picture
Figure 2. Global Immuno-oncology Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Immuno-oncology Drugs Market Share by Type: 2024 VS 2031
Figure 4. Immune Checkpoint Inhibitors Features
Figure 5. Immune System Modulators Features
Figure 6. Cancer Vaccines Features
Figure 7. Oncolytic Virus Features
Figure 8. Others Features
Figure 9. Global Immuno-oncology Drugs Market Size by Application (2020-2031) & (US$ Million)
Figure 10. Global Immuno-oncology Drugs Market Share by Application: 2024 VS 2031
Figure 11. Hospitals Case Studies
Figure 12. Clinics Case Studies
Figure 13. Ambulatory Surgical Centers Case Studies
Figure 14. Immuno-oncology Drugs Report Years Considered
Figure 15. Global Immuno-oncology Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 16. Global Immuno-oncology Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Immuno-oncology Drugs Market Share by Region: 2024 VS 2031
Figure 18. Global Immuno-oncology Drugs Market Share by Players in 2024
Figure 19. Global Top Immuno-oncology Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immuno-oncology Drugs as of 2024)
Figure 20. The Top 10 and 5 Players Market Share by Immuno-oncology Drugs Revenue in 2024
Figure 21. North America Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. North America Immuno-oncology Drugs Market Share by Country (2020-2031)
Figure 23. United States Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Canada Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Immuno-oncology Drugs Market Share by Country (2020-2031)
Figure 27. Germany Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. France Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. U.K. Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Italy Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Russia Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Nordic Countries Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Immuno-oncology Drugs Market Share by Region (2020-2031)
Figure 35. China Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Japan Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. South Korea Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Southeast Asia Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. India Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Australia Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Immuno-oncology Drugs Market Share by Country (2020-2031)
Figure 43. Mexico Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Brazil Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Immuno-oncology Drugs Market Share by Country (2020-2031)
Figure 47. Turkey Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Saudi Arabia Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. UAE Immuno-oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Amgen, Inc Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 51. AstraZeneca, Plc Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 52. Bristol-Myers Squibb Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 53. Celgene Corporation Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 54. Eli Lilly and Company Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 55. Merck & Co. Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 56. Hoffmann-La Roche AG Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 57. Johnson & Johnson Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 58. Novartis International AG Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 59. AbbVie, Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 60. Pfizer Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 61. Sanofi S.A. Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 62. EMD Serono, Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 63. Gilead Sciences Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 64. Prometheus Therapeutics & Diagnostics Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 65. Aduro BioTech Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 66. Galena Biopharma Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 67. Bavarian Nordic Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 68. Celldex Therapeutics Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 69. ImmunoCellular Therapeutics Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 70. Incyte Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 71. Dendreon Corporation Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 72. Agilent Technologies Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 73. Agenus Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 74. Enzo Biochem, Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 75. Lonza Group Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 76. Bio-Rad Laboratories, Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 77. Avantor, Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 78. Spring Bank Pharmaceuticals, Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 79. Ferring Pharmaceuticals Revenue Growth Rate in Immuno-oncology Drugs Business (2020-2025)
Figure 80. Bottom-up and Top-down Approaches for This Report
Figure 81. Data Triangulation
Figure 82. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Outdoor Shed Market Research Report 2025
Sep 09, 25
Global Residential Outdoor Cabinet Market Research Report 2025
Sep 09, 25
Global Outdoor Storage Cabinet Market Research Report 2025
Sep 09, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232